EMG
LXRX icon

Ellington Management Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Ellington Management Group’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-55,000
Closed -$471K – 693
2018
Q1 		$471K Buy
+55,000
New +$509K 0.07% 425
2017
Q4 		– Sell
-24,100
Closed -$296K – 724
2017
Q3 		$296K Buy
+24,100
New +$356K 0.09% 385
2016
Q3 		– Sell
-11,700
Closed -$168K – 666
2016
Q2 		$168K Sell
11,700
-15,600
-57% -$212K 0.23% 175
2016
Q1 		$326K Buy
+27,300
New +$286K 0.14% 215
2015
Q3 		– Sell
-15,000
Closed -$121K – 809
2015
Q2 		$121K Buy
+15,000
New +$110K 0.03% 638

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SGA
Sector Gamma AS Oslo, Norway $423M AUM 17.56% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return